1356166-70-5

Basic information

• Product Name: 6-p-tolyl-2-(3,4,5-trimethoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazole-6-carbaldehyde
• Synonyms: 6-p-tolyl-2-(3,4,5-trimethoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazole-6-carbaldehyde
• CAS NO: 1356166-70-5
• Molecular Weight: 409.466
• Mol File: 1356166-70-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 6-p-tolyl-2-(3,4,5-trimethoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazole-6-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 6-p-tolyl-2-(3,4,5-trimethoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazole-6-carbaldehyde(1356166-70-5)
• EPA Substance Registry System: 6-p-tolyl-2-(3,4,5-trimethoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazole-6-carbaldehyde(1356166-70-5)

Safety Data

• Hazardous Substances Data: 1356166-70-5(Hazardous Substances Data)

Upstream product

• 68-12-2 N,N-dimethyl-formamide 
• 91918-59-1 6-p-tolyl-2-(3,4,5-trimethoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazole 
• 28004-59-3 2-(3,4,5-trimethoxyphenyl)-5-amino-1,3,4-thiadiazole 
• 118-41-2 Eudesmic acid 

Downstream Products

• 1629164-38-0 (E)-5-fluoro-3-((6-p-tolyl-2-(3,4,5-trimethoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylene)indolin-2-one 
• 1629164-39-1 (E)-5-methoxy-3-((6-p-tolyl-2-(3,4,5-trimethoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylene)indolin-2-one 
• 1629164-40-4 (E)-5-chloro-3-((6-p-tolyl-2-(3,4,5-trimethoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylene)indolin-2-one 
• 1629164-41-5 (E)-6-chloro-3-((6-p-tolyl-2-(3,4,5-trimethoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylene)indolin-2-one 
• 1629164-42-6 (E)-3-((6-p-tolyl-2-(3,4,5-trimethoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylene)indolin-2-one 

Relevant articles and documents

Synthesis and biological evaluation of imidazo[2,1-b][1,3,4]thiadiazole- linked oxindoles as potent tubulin polymerization inhibitors

A series of imidazo[2,1-b][1,3,4]thiadiazole-linked oxindoles composed of an A, B, C and D ring system were synthesized and investigated for anti-proliferative activity in various human cancer cell lines; test compounds were variously substituted at rings C and D. Among them, compounds 7 ((E)-5-fluoro-3-((6-p-tolyl-2-(3,4,5-trimethoxyphenyl)-imidazo[2,1-b][1,3,4] thiadiazol-5-yl)methylene)indolin-2-one), 11 ((E)-3-((6-p-tolyl-2-(3,4,5- trimethoxyphenyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl)methylene)indolin-2-one), and 15 ((E)-6-chloro-3-((6-phenyl-2-(3,4,5-trimethoxyphenyl)imidazo[2,1-b][1,3, 4]thiadiazol-5-yl)methylene)indolin-2-one) exhibited potent anti-proliferative activity. Treatment with these three compounds resulted in accumulation of cells in G2/M phase, inhibition of tubulin assembly, and increased cyclin-B1 protein levels. Compound 7 displayed potent cytotoxicity, with an IC50 range of 1.1-1.6 μM, and inhibited tubulin polymerization with an IC50 value (0.15 μM) lower than that of combretastatin A-4 (1.16 μM). Docking studies reveal that compounds 7 and 11 bind with αAsn101, βThr179, and βCys241 in the colchicine binding site of tubulin. Imidazzling microtubule blockers! A series of imidazo[2,1-b][1,3,4] thiadiazole-linked oxindole conjugates were synthesized and evaluated for anticancer potential. Conjugate 7 displayed promising cytotoxicity, arrested cells at the G2/M phase, and showed potent tubulin polymerization inhibition with an IC50 value of 0.15 μM.